J&J Medical Connect
Immunology
Immunology

Congress Materials – American College of Gastroenterology (ACG 2026)

 

2026 American College of Gastroenterology | Oct 9-14 | Nashville, TN

This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.

Changes in Intestinal Stenosis Among Patients With Moderately to Severely Active Crohn’s Disease Treated With Guselkumab: Results From the Phase 3 GALAXI and GRAVITI Studies

Walter Reinisch, Anita Afzali, Hamid Bassiri, Rian Van Rampelbergh, Wilhelmus van Duijnhoven, Shashi Adsul, Dylan Richards, Nat Terry, David Rubin


This document will be available on October 13, 2026

Deep Remission in Guselkumab-Treated Participants With Moderately to Severely Active Crohn’s Disease Through 3 Years: Results From the GALAXI 2 and 3 Studies

David T. Rubin, Anita Afzali, Christopher Busse, Rian Van Rampelbergh, Wilhelmus Van Duijnhoven, Marla Dubinsky, Geert D’Haens


This document will be available on October 11, 2026

Efficacy and Safety of Guselkumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn’s Disease: Results Through Week 144 From the Phase 3 GALAXI 2 & 3 Studies

Bruce E. Sands, Walter Reinisch, Geert D’Haens, Remo Panaccione, Anita Afzali, David Rubin, Jacqueline Yee, Wilhelmus van Duijnhoven, Christopher Corbett, Rian van Rampelbergh, Tadakazu Hisamatsu, Silvio Danese


This document will be available on October 11, 2026

Efficacy and Safety of the First Co-Antibody Therapy, JNJ-78934804, in Patients With Moderately to Severely Active Crohn’s Disease Refractory to 2 or More Systemic Therapy Mechanisms

Vipul Jairath, Geert D'Haens, Iris Dotan, Nat Terry, Monica Walker, Vanessa Bundy, Hayley Perry, Dylan Richards, Marion Vetter, Taku Kobayashi, Stefan Schreiber, Bruce E. Sands


This document will be available on October 11, 2026

Efficacy of Guselkumab in Perianal Fistulizing Crohn's Disease: Week 24 Results From the Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter FUZION Study

Bruce E. Sands, Alisa Hart, Vipul Jairath, Tadakazu Hisamatsu, Axel Dignass, Antonio Spinelli, Susan Connor, André D’Hoore, Walter Reinisch, Silvio Danese, David Schwartz, Julian Panés, Bram Verstockt, Anton Stift, Maciej Nazar, Jacqueline Van Denderen, Talia Gramiccia, Takehiko Sakamoto, Koji Masuda, Shusheng Xu, Ivana Bravatà, Geert D’Haens, Laurent Peyrin-Biroulet


This document will be available on October 11, 2026

Endoscopic Outcomes of Ulcer Size and Ulcerated Surface Over One Year Across Bowel Segments in Participants With Crohn’s Disease Treated With Guselkumab: Pooled GALAXI 2 and GALAXI 3, Phase 3 Trials Analysis

Alessandro Armuzzi, Mathurin Fumery, Bruce E. Sands, Marc Ferrante, Tim Raine, Rian Van Rampelbergh, Maciej Nazar, Victoria McCaffrey, Jacqueline Van Denderen, Raja Atreya


This document will be available on October 11, 2026

Healthcare Professionals’ Perceptions of Intravenous and Subcutaneous Treatment Administration For Inflammatory Bowel Disease: A Real-World Study in the United States

Sumesh Kachroo, Pahul Lehal, William Jones, Fatima Dawod


This document will be available on October 11, 2026

Histologic and Endoscopic Efficacy of Icotrokinra, a First-in-Class Targeted Oral Peptide That Precisely Blocks the IL-23 Receptor, in Ulcerative Colitis: Outcomes From the ANTHEM-UC Study

Karen Chachu, Jimmy Limdi, Edward V. Loftus, Jr., Vipul Jairath, Maria Abreu, Minhu Chen, Edouard Louis, Katsuyoshi Matsuoka, Lindsey Surace, Ngozi Erondu, Martha Zeeman, Jia Zhan, Mary Ellen Frustaci, Grazyna Rydzewska, Britta Siegmund


This document will be available on October 11, 2026

Histology Outcomes Over Time in Patients With Moderately to Severely Active Ulcerative Colitis Treated With Guselkumab in the QUASAR Long-Term Extension Study

David Rubin, Jessica Allegretti, Yelina Alvarez, Thomas Baker, Shashi Adsul, Darren Piscitelli, Ye Miao, Laurent Peyrin-Biroulet


This document will be available on October 13, 2026

Long-Term Efficacy and Safety of Icotrokinra, A First-in-Class Targeted Oral Peptide That Precisely Blocks the IL-23 Receptor, in Ulcerative Colitis: Results From the ANTHEM-UC Long Term Extension

Maria T. Abreu, Britta Siegmund, Lindsey Surace, Ngozi Erondu, Minhu Chen, Karen Chachu, Edouard Louis, Katsuyoshi Matsuoka, Jimmy Limdi, Nicole Houck, Mary Ellen Frustaci, Jia Zhan, Grazyna Rydzewska, Vipul Jairath, Edward V. Loftus, Jr.


This document will be available on October 13, 2026

Patient Characteristics, Treatment Patterns, and Healthcare Resource Utilization in Patients With Inflammatory Bowel Disease Who Initiated Treatment With Guselkumab

Hsien-Yen Chang, Sumesh Kachroo


This document will be available on October 11, 2026

Pharmacokinetics and Exposure-Response Relationships of Subcutaneous Guselkumab Maintenance in Participants With Moderately to Severely Active Crohn’s Disease

Bruce E. Sands, Geert D’Haens, Omoniyi Adedokun, Tae Eun Yang, David Rubin, Nat Terry, Rian Van Rampelbergh, Marion Vetter, Tadakazu Hisamatsu, Remo Panaccione, Silvio Danese


This document will be available on October 11, 2026

Pharmacokinetics and Exposure-Response Relationships of Subcutaneous Guselkumab Maintenance in Participants With Moderately to Severely Active Ulcerative Colitis

David T. Rubin, Laurent Peyrin-Biroulet, Jie Shao, Yu Kyoung Cho, Jafar Sadik Shaik, Millie Long, Silvio Danese, Yelina Alvarez, Marion Vetter, Thomas Baker, Jessica Allegretti, Tadakazu Hisamatsu


This document will be available on October 11, 2026

Prevalence, Unmet Needs, Treatment Patterns and Healthcare Resource Utilization of Patients With Fistulizing Crohn's Disease

Hsien-Yen Chang, Sumesh Kachroo, Jennifer Seminerio-Diehl


This document will be available on October 11, 2026

Symptomatic and Biomarker Outcomes Among Participants Treated with Guselkumab Not in Clinical Response at Week 12: Results From the Phase 3 QUASAR Induction Study

Jessica Allegretti, Alessandro Armuzzi, Jordan Axelrad, Yelina Alvarez, Thomas Baker, Caroline Kerner, Shashi Adsul, Ye Miao, Hongyan Zhang, Axel Dignass


This document will be available on October 11, 2026

The Efficacy and Safety of Guselkumab in Patients With Moderate to Severe Ulcerative Colitis Through Two Years: ASTRO Week 96 Results

Millie D. Long, Laurent Peyrin-Biroulet, Tadakazu Hisamatsu, Jessica Allegretti, Yelina Alvarez, Thomas Baker, Karen Hertzog, Chenglong Han, Hongyan Zhang, Ye Miao, David Rubin, Silvio Danese


This document will be available on October 11, 2026

Time to First Indication of Disease Progression in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Guselkumab Phase 3 QUASAR Maintenance

Jessica Allegretti, Brian Bressler, Tadakazu Hisamatsu, Bruce E. Sands, Yelina Alvarez, Thomas Baker, Shashi Adsul, Ye Miao, Hongyan Zhang, David Rubin, Axel Dignass


This document will be available on October 11, 2026

Unsupervised Machine Learning to Identify Distinct Patient-Level Response Patterns to Guselkumab in Ulcerative Colitis: Post Hoc Analysis From the ASTRO Trial

Stefan Schreiber, Silvio Danese, Sudheer Rani, Thomas Baker, Yelina Alvarez, Long-Long Gao, Zijiang Yang, Tim Hoops, Millie D. Long


This document will be available on October 11, 2026

 

Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.

J&J Medical Connect

Connect with us

Connect with us

Would you like to clear and leave your conversation? Message history will be lost.